LUNG MAP (master protocol- Step 0)Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial) - Mercy Medical Center

LUNG MAP (master protocol- Step 0)Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

Posted on: January 28, 2020

Participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies. Eligibility includes being at least 18 years old and:

•Patients with adequate archival tissue should be registered directly to Step 1, without registering to Step 0. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing. Patients who need a fresh biopsy to obtain adequate tumor tissue must also submit whole blood for ctDNA testing. These patients must be registered to Step 0 to obtain a patient ID number for the submission
•Patients registered to Step 0 are not registered to the LungMAP protocol. To participate in LungMAP, patients must be registered to Step 1 after evaluation of patient eligibility, including tumor tissue adequacy

 

Sub -study registration Step 1 eligibility will depend on what sub-study you are randomized to.

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center